Cargando…

Immunogenicity and safety of the non-typable Haemophilus influenzae–Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial

A candidate AS01-adjuvanted vaccine containing four surface proteins from non-typable Haemophilus influenzae and Moraxella catarrhalis (NTHi-Mcat) has been developed to help prevent exacerbations of chronic obstructive pulmonary disease (COPD). Sequential administration of different vaccines contain...

Descripción completa

Detalles Bibliográficos
Autores principales: Galgani, Ilaria, Põder, Airi, Jõgi, Rain, Anttila, Veli-Jukka, Milleri, Stefano, Borobia, Alberto M., Launay, Odile, Testa, Marco, Casula, Daniela, Grassano, Luca, Tasciotti, Annaelisa, Dozot, Marie, Arora, Ashwani K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078133/
https://www.ncbi.nlm.nih.gov/pubmed/36974988
http://dx.doi.org/10.1080/21645515.2023.2187194
_version_ 1785020450540093440
author Galgani, Ilaria
Põder, Airi
Jõgi, Rain
Anttila, Veli-Jukka
Milleri, Stefano
Borobia, Alberto M.
Launay, Odile
Testa, Marco
Casula, Daniela
Grassano, Luca
Tasciotti, Annaelisa
Dozot, Marie
Arora, Ashwani K.
author_facet Galgani, Ilaria
Põder, Airi
Jõgi, Rain
Anttila, Veli-Jukka
Milleri, Stefano
Borobia, Alberto M.
Launay, Odile
Testa, Marco
Casula, Daniela
Grassano, Luca
Tasciotti, Annaelisa
Dozot, Marie
Arora, Ashwani K.
author_sort Galgani, Ilaria
collection PubMed
description A candidate AS01-adjuvanted vaccine containing four surface proteins from non-typable Haemophilus influenzae and Moraxella catarrhalis (NTHi-Mcat) has been developed to help prevent exacerbations of chronic obstructive pulmonary disease (COPD). Sequential administration of different vaccines containing the same AS01-adjuvant system could lead to immune interference. We compared administration of NTHi-Mcat following AS01-adjuvanted recombinant zoster vaccine (RZV) versus NTHi-Mcat alone. This phase 2a, open-label trial (NCT03894969) randomized healthy current or former smokers (50–80 years) without COPD to administration of NTHi-Mcat at 1, 3 or 6 months after RZV or to NTHi-Mcat alone (2-dose for both vaccines). Primary outcome was non-inferiority of the humoral immune response to NTHi-Mcat administered 1 month after RZV versus NTHi-Mcat alone, evaluated by specific antibody geometric mean concentration (GMC) ratio with 95% confidence intervals (CIs). The per-protocol set included 411 participants. Primary objective was met; lower limit of the 95%CI for the GMC ratio above 0.667 for all four vaccine antigens, 1 month after the second NTHi-Mcat dose. NTHi-Mcat induced similar immune response regardless of whether administered alone or 1, 3 or 6 months following RZV. Safety and reactogenicity profiles were acceptable; adverse event frequency was similar among study groups. Injection site pain was the most common symptom. No new safety concerns were identified. The study demonstrated non-inferiority of the immune response elicited by NTHi-Mcat administered sequentially to RZV versus NTHi-Mcat alone, indicating no immune interference. Starting from 1 month, no specific interval is required between RZV and NTHi-Mcat containing the same AS01-adjuvant system components in different quantities.
format Online
Article
Text
id pubmed-10078133
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-100781332023-04-07 Immunogenicity and safety of the non-typable Haemophilus influenzae–Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial Galgani, Ilaria Põder, Airi Jõgi, Rain Anttila, Veli-Jukka Milleri, Stefano Borobia, Alberto M. Launay, Odile Testa, Marco Casula, Daniela Grassano, Luca Tasciotti, Annaelisa Dozot, Marie Arora, Ashwani K. Hum Vaccin Immunother Novel Vaccines A candidate AS01-adjuvanted vaccine containing four surface proteins from non-typable Haemophilus influenzae and Moraxella catarrhalis (NTHi-Mcat) has been developed to help prevent exacerbations of chronic obstructive pulmonary disease (COPD). Sequential administration of different vaccines containing the same AS01-adjuvant system could lead to immune interference. We compared administration of NTHi-Mcat following AS01-adjuvanted recombinant zoster vaccine (RZV) versus NTHi-Mcat alone. This phase 2a, open-label trial (NCT03894969) randomized healthy current or former smokers (50–80 years) without COPD to administration of NTHi-Mcat at 1, 3 or 6 months after RZV or to NTHi-Mcat alone (2-dose for both vaccines). Primary outcome was non-inferiority of the humoral immune response to NTHi-Mcat administered 1 month after RZV versus NTHi-Mcat alone, evaluated by specific antibody geometric mean concentration (GMC) ratio with 95% confidence intervals (CIs). The per-protocol set included 411 participants. Primary objective was met; lower limit of the 95%CI for the GMC ratio above 0.667 for all four vaccine antigens, 1 month after the second NTHi-Mcat dose. NTHi-Mcat induced similar immune response regardless of whether administered alone or 1, 3 or 6 months following RZV. Safety and reactogenicity profiles were acceptable; adverse event frequency was similar among study groups. Injection site pain was the most common symptom. No new safety concerns were identified. The study demonstrated non-inferiority of the immune response elicited by NTHi-Mcat administered sequentially to RZV versus NTHi-Mcat alone, indicating no immune interference. Starting from 1 month, no specific interval is required between RZV and NTHi-Mcat containing the same AS01-adjuvant system components in different quantities. Taylor & Francis 2023-03-28 /pmc/articles/PMC10078133/ /pubmed/36974988 http://dx.doi.org/10.1080/21645515.2023.2187194 Text en © 2023 GSK. Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
spellingShingle Novel Vaccines
Galgani, Ilaria
Põder, Airi
Jõgi, Rain
Anttila, Veli-Jukka
Milleri, Stefano
Borobia, Alberto M.
Launay, Odile
Testa, Marco
Casula, Daniela
Grassano, Luca
Tasciotti, Annaelisa
Dozot, Marie
Arora, Ashwani K.
Immunogenicity and safety of the non-typable Haemophilus influenzae–Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial
title Immunogenicity and safety of the non-typable Haemophilus influenzae–Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial
title_full Immunogenicity and safety of the non-typable Haemophilus influenzae–Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial
title_fullStr Immunogenicity and safety of the non-typable Haemophilus influenzae–Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial
title_full_unstemmed Immunogenicity and safety of the non-typable Haemophilus influenzae–Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial
title_short Immunogenicity and safety of the non-typable Haemophilus influenzae–Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial
title_sort immunogenicity and safety of the non-typable haemophilus influenzae–moraxella catarrhalis (nthi-mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: results from a randomized, phase 2a, non-inferiority trial
topic Novel Vaccines
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078133/
https://www.ncbi.nlm.nih.gov/pubmed/36974988
http://dx.doi.org/10.1080/21645515.2023.2187194
work_keys_str_mv AT galganiilaria immunogenicityandsafetyofthenontypablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccineadministeredfollowingtherecombinantzostervaccineversusadministrationaloneresultsfromarandomizedphase2anoninferioritytrial
AT poderairi immunogenicityandsafetyofthenontypablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccineadministeredfollowingtherecombinantzostervaccineversusadministrationaloneresultsfromarandomizedphase2anoninferioritytrial
AT jogirain immunogenicityandsafetyofthenontypablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccineadministeredfollowingtherecombinantzostervaccineversusadministrationaloneresultsfromarandomizedphase2anoninferioritytrial
AT anttilavelijukka immunogenicityandsafetyofthenontypablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccineadministeredfollowingtherecombinantzostervaccineversusadministrationaloneresultsfromarandomizedphase2anoninferioritytrial
AT milleristefano immunogenicityandsafetyofthenontypablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccineadministeredfollowingtherecombinantzostervaccineversusadministrationaloneresultsfromarandomizedphase2anoninferioritytrial
AT borobiaalbertom immunogenicityandsafetyofthenontypablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccineadministeredfollowingtherecombinantzostervaccineversusadministrationaloneresultsfromarandomizedphase2anoninferioritytrial
AT launayodile immunogenicityandsafetyofthenontypablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccineadministeredfollowingtherecombinantzostervaccineversusadministrationaloneresultsfromarandomizedphase2anoninferioritytrial
AT testamarco immunogenicityandsafetyofthenontypablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccineadministeredfollowingtherecombinantzostervaccineversusadministrationaloneresultsfromarandomizedphase2anoninferioritytrial
AT casuladaniela immunogenicityandsafetyofthenontypablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccineadministeredfollowingtherecombinantzostervaccineversusadministrationaloneresultsfromarandomizedphase2anoninferioritytrial
AT grassanoluca immunogenicityandsafetyofthenontypablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccineadministeredfollowingtherecombinantzostervaccineversusadministrationaloneresultsfromarandomizedphase2anoninferioritytrial
AT tasciottiannaelisa immunogenicityandsafetyofthenontypablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccineadministeredfollowingtherecombinantzostervaccineversusadministrationaloneresultsfromarandomizedphase2anoninferioritytrial
AT dozotmarie immunogenicityandsafetyofthenontypablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccineadministeredfollowingtherecombinantzostervaccineversusadministrationaloneresultsfromarandomizedphase2anoninferioritytrial
AT aroraashwanik immunogenicityandsafetyofthenontypablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccineadministeredfollowingtherecombinantzostervaccineversusadministrationaloneresultsfromarandomizedphase2anoninferioritytrial